
|Videos|November 9, 2017
Dr. Feldman on Durvalumab for Patients With Lung Cancer
Author(s)Lawrence E. Feldman, MD
Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.
Advertisement
Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.
Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.
This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































